Bayer AG is initiating a large Phase III clinical trial program enrolling more than 30,000 patients to investigate its next-generation Factor XIa inhibitor asundexian, with the goal of developing an effective oral anticoagulant with an improved safety profile over the current standard of care, its own Xarelto (rivaroxaban) and Bristol Myers Squibb Company/Pfizer Inc.'s Eliquis (apixaban).
Bayer Outlines Asundexian Phase III Plan, Hoping To Prove Safety Benefit Over Eliquis
The Factor XIa inhibitor could be an effective anticoagulant without the increased risk in bleeding associated with current Factor Xa inhibitors, but the profile will need to be confirmed in Phase III.
